These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 36877951)

  • 1. Financial toxicity from newly approved second-/third-line agents in metastatic urothelial carcinoma.
    Benjamin DJ; Lythgoe MP; Rezazadeh A
    BJU Int; 2023 Jun; 131(6):691-693. PubMed ID: 36877951
    [No Abstract]   [Full Text] [Related]  

  • 2. ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma.
    Powles T; Bellmunt J; Comperat E; De Santis M; Huddart R; Loriot Y; Necchi A; Valderrama BP; Ravaud A; Shariat SF; Szabados B; van der Heijden MS; Gillessen S;
    Ann Oncol; 2024 Jun; 35(6):485-490. PubMed ID: 38490358
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.
    Tilgener C; Bedke J
    Eur Urol; 2024 Jun; 85(6):591-592. PubMed ID: 38538421
    [No Abstract]   [Full Text] [Related]  

  • 4. The clinical use of enfortumab vedotin and pembrolizumab in patients with advanced urothelial carcinoma: using clinical judgement over treatment criteria.
    Apolo AB; Bellmunt J; Cordes L; Gupta S; Powles T; Rosenberg JE; Van Der Heijden MS
    ESMO Open; 2024 Sep; 9(9):103725. PubMed ID: 39236601
    [No Abstract]   [Full Text] [Related]  

  • 5. [Not Available].
    Aktuelle Urol; 2024 Aug; 55(4):297-298. PubMed ID: 39047749
    [No Abstract]   [Full Text] [Related]  

  • 6. Bempegaldesleukin/Nivolumab and Challenges in First-line Treatment of Metastatic Urothelial Carcinoma.
    Miron B; Geynisman DM
    Eur Urol; 2022 Oct; 82(4):374-376. PubMed ID: 35752503
    [No Abstract]   [Full Text] [Related]  

  • 7. Editorial Comment on Real-world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan.
    Ishihara H; Takagi T
    Int J Urol; 2024 May; 31(5):559-560. PubMed ID: 38366784
    [No Abstract]   [Full Text] [Related]  

  • 8. Editorial Comment to Real-world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan.
    Kondo T
    Int J Urol; 2024 May; 31(5):560-561. PubMed ID: 38424666
    [No Abstract]   [Full Text] [Related]  

  • 9. The co-expression of antigen targets as a rationale for ADC combination in urothelial cancer.
    Bertucci F; de Nonneville A; Finetti P; Cohendet A; Guille A; Mamessier E
    Ann Oncol; 2024 May; 35(5):477-478. PubMed ID: 38364991
    [No Abstract]   [Full Text] [Related]  

  • 10. [Second-line treatment of metastatic urothelial carcinoma : Update immuno-oncology].
    Zschäbitz S; Niegisch G
    Urologe A; 2020 Jul; 59(7):804-809. PubMed ID: 32472222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re: EV-301 Long-term Outcomes: 24-month Findings from the Phase III Trial of Enfortumab Vedotin Versus Chemotherapy in Patients with Previously Treated Advanced Urothelial Carcinoma.
    Drake MJ; Birder LA
    Eur Urol; 2024 Aug; 86(2):183-184. PubMed ID: 38538426
    [No Abstract]   [Full Text] [Related]  

  • 12. A new standard of care for advanced-stage urothelial carcinoma.
    Sidaway P
    Nat Rev Clin Oncol; 2024 May; 21(5):336. PubMed ID: 38509334
    [No Abstract]   [Full Text] [Related]  

  • 13. Is there a role for pembrolizumab beyond progression in urothelial carcinoma?
    Taguchi S; Kawai T; Nakagawa T; Kume H
    BJU Int; 2024 Jul; 134(1):43-44. PubMed ID: 38073020
    [No Abstract]   [Full Text] [Related]  

  • 14. Enfortumab vedotin and pembrolizumab combination as a relevant game changer in urothelial carcinoma: What is left behind?
    Bellmunt J; Nadal R
    Med; 2024 Jun; 5(6):490-492. PubMed ID: 38878766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [First line therapy for locally advanced or metastatic urothelial cancer : A randomized double blind phase III multicenter study on adjuvant nivolumab therapy versus placebo in patients with invasive high-risk urothelial cancer (CheckMate 274)-AB 58/17 of the AUO].
    Rexer H; Ohlmann CH; Gschwend J;
    Urologe A; 2017 Oct; 56(10):1331-1332. PubMed ID: 28779222
    [No Abstract]   [Full Text] [Related]  

  • 16. Erdafitinib's Road to Approval and Use in Urothelial Carcinoma.
    Hanna K
    Oncology (Williston Park); 2023 Jun; 37(6):260-261. PubMed ID: 37343205
    [No Abstract]   [Full Text] [Related]  

  • 17. Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
    Catalano M; Santoni M; Roviello G
    Eur Urol; 2024 Sep; 86(3):283. PubMed ID: 38744633
    [No Abstract]   [Full Text] [Related]  

  • 18. Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
    Klümper N; Vera-Badillo FE; Eckstein M; Hadaschik B; Grünwald V
    Eur Urol; 2024 Sep; 86(3):280-281. PubMed ID: 38599990
    [No Abstract]   [Full Text] [Related]  

  • 19. Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
    Chen DC; AlSaffar H; Graefen H; Perera S; Mazzone E; Perera ML; Lawrentschuk N; Murphy DG
    Eur Urol; 2024 Sep; 86(3):282-283. PubMed ID: 38631993
    [No Abstract]   [Full Text] [Related]  

  • 20. [First-line treatment of metastatic urothelial carcinoma : Update immuno-oncology].
    Zacharis A; Grüllich C
    Urologe A; 2020 Jul; 59(7):797-803. PubMed ID: 32500171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.